
AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …

Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which …

Novo Nordisk has taken the opportunity at the American Diabetes Association (ADA) 79th Scientific Sessions to pull back the curtain …

Patients taking some newer diabetes medications – SGLT2 inhibitors – have been warned that they may be at risk of …

A diabetes drug may help people quit smoking, according to researchers at the University of Texas Health Science Center at …

The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the …

Sanofi and Lexicon’s Zynquista (sotagliflozin) has hit a hurdle on its way to US approval for the treatment of type …

AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically predisposed to developing type 2 …

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …

The FDA is cracking down on those selling ‘dietary supplements’, having sent warning letters to companies who claim, without proof, …

Michael Connellan, Head of External Affairs at the type 1 diabetes charity JDRF, discusses the results of a recent survey …

Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …